<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               14 CLINICAL STUDIES<BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     14.1 Adults<BR>                     <BR>                        <BR>                           Therapy-Naive Adults: CNA30024 was a multicenter, double-blind, controlled study in which 649 HIV-1-infected, therapy-naive adults were randomized and received either ZIAGEN (300 mg twice daily), lamivudine (150 mg twice daily), and efavirenz (600 mg once daily) or zidovudine (300 mg twice daily), lamivudine (150 mg twice daily), and efavirenz (600 mg once daily). The duration of double-blind treatment was at least 48 weeks. Study participants were: male (81%), Caucasian (51%), black (21%), and Hispanic (26%). The median age was 35 years, the median pretreatment CD4+ cell count was 264 cells/mm3, and median plasma HIV-1 RNA was 4.79 log10 copies/mL. The outcomes of randomized treatment are provided in Table 7.<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" width="0.000" ID="id_2c097fcb-b5bf-4fe7-ad5b-c9e7060228e9"><BR>                           <caption ID="id_1e6d9d07-0c89-4513-9fcc-9d21bc23a6d0">Table 7. Outcomes of Randomized Treatment Through Week 48 (CNA30024) </caption><BR>                           <col/><BR>                           <col/><BR>                           <col/><BR>                           <tfoot ID="id_d1cb535d-79bf-4a8e-9037-6deec61b4639"><BR>                              <tr><BR>                                 <td align="left" valign="top" colspan="3" rowspan="1" styleCode="Lrule Rrule"><BR>                                    <paragraph><BR>                                       <sup>*</sup> Patients achieved and maintained confirmed HIV-1 RNA &#8804;50&#160;copies/mL (&lt;400&#160;copies/mL) through Week 48 (Roche AMPLICOR Ultrasensitive HIV-1 MONITOR<sup>&#174;</sup> standard test 1.0 PCR).</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="left" valign="top" colspan="3" rowspan="1" styleCode="Lrule Rrule"><BR>                                    <paragraph><BR>                                       <sup>&#8224;</sup> Includes viral rebound, insufficient viral response according to the investigator, and failure to achieve confirmed &#8804;50&#160;copies/mL by Week 48.</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="left" valign="top" colspan="3" rowspan="1" styleCode="Lrule Botrule Rrule"><BR>                                    <paragraph><BR>                                       <sup>&#8225;</sup> Includes consent withdrawn, lost to follow up, protocol violations, those with missing data, clinical progression, and other.</paragraph><BR>                                 </td><BR>                              </tr><BR>                           </tfoot><BR>                           <tbody><BR>                              <tr ID="id_35feb241-d2a4-4d15-a1d4-edd40253a5c8"><BR>                                 <td align="center" valign="bottom" rowspan="1" styleCode="Botrule Toprule Rrule Lrule"><BR>                                    <paragraph>Outcome</paragraph><BR>                                 </td><BR>                                 <td align="center" valign="bottom" rowspan="1" styleCode="Botrule Rrule"><BR>                                    <paragraph>ZIAGEN plus Lamivudine plus Efavirenz</paragraph><BR>                                    <paragraph>(n = 324)</paragraph><BR>                                 </td><BR>                                 <td align="center" valign="bottom" rowspan="1" styleCode="Botrule Rrule"><BR>                                    <paragraph>Zidovudine plus Lamivudine plus Efavirenz</paragraph><BR>                                    <paragraph>(n = 325)</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr ID="id_283331dc-02fb-4041-af66-5563301fcf02"><BR>                                 <td align="left" valign="top" rowspan="1" styleCode="Lrule Rrule"><BR>                                    <paragraph>Responder<sup>*</sup><BR>                                    </paragraph><BR>                                 </td><BR>                                 <td align="center" valign="bottom" rowspan="1" styleCode="Rrule"><BR>                                    <paragraph>69% (73%)</paragraph><BR>                                 </td><BR>                                 <td align="center" valign="bottom" rowspan="1" styleCode="Rrule"><BR>                                    <paragraph>69% (71%)</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr ID="id_75b7658b-e7ee-47aa-a8d6-dc6830f1308f"><BR>                                 <td align="left" valign="top" rowspan="1" styleCode="Lrule Rrule"><BR>                                    <paragraph>Virologic failures<sup>&#8224;</sup><BR>                                    </paragraph><BR>                                 </td><BR>                                 <td align="center" valign="bottom" rowspan="1" styleCode="Rrule"><BR>                                    <paragraph>6%</paragraph><BR>                                 </td><BR>                                 <td align="center" valign="bottom" rowspan="1" styleCode="Rrule"><BR>                                    <paragraph>4%</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr ID="id_736f6794-1c15-4883-81eb-882fb6005267"><BR>                                 <td align="left" valign="top" rowspan="1" styleCode="Lrule Rrule"><BR>                                    <paragraph>Discontinued due to adverse reactions</paragraph><BR>                                 </td><BR>                                 <td align="center" valign="bottom" rowspan="1" styleCode="Rrule"><BR>                                    <paragraph>14%</paragraph><BR>                                 </td><BR>                                 <td align="center" valign="bottom" rowspan="1" styleCode="Rrule"><BR>                                    <paragraph>16%</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr ID="id_3ed735ff-df36-4791-85cf-5dcac9a6e39e"><BR>                                 <td align="left" valign="top" rowspan="1" styleCode="Lrule Botrule Rrule"><BR>                                    <paragraph>Discontinued due to other reasons<sup>&#8225;</sup><BR>                                    </paragraph><BR>                                 </td><BR>                                 <td align="center" valign="bottom" rowspan="1" styleCode="Botrule Rrule"><BR>                                    <paragraph>10%</paragraph><BR>                                 </td><BR>                                 <td align="center" valign="bottom" rowspan="1" styleCode="Botrule Rrule"><BR>                                    <paragraph>11%</paragraph><BR>                                 </td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>After 48 weeks of therapy, the median CD4+ cell count increases from baseline were 209 cells/mm3 in the group receiving ZIAGEN and 155 cells/mm3 in the zidovudine group. Through Week 48, 8 subjects (2%) in the group receiving ZIAGEN (5 CDC classification C events and 3 deaths) and 5 subjects (2%) on the zidovudine arm (3 CDC classification C events and 2 deaths) experienced clinical disease progression.<BR>                        CNA3005 was a multicenter, double-blind, controlled study in which 562 HIV-1-infected, therapy-naive adults were randomized to receive either ZIAGEN (300 mg twice daily) plus COMBIVIR (lamivudine 150 mg/zidovudine 300 mg twice daily), or indinavir (800 mg 3 times a day) plus COMBIVIR twice daily. The study was stratified at randomization by pre-entry plasma HIV-1 RNA 10,000 to 100,000 copies/mL and plasma HIV-1 RNA greater than 100,000 copies/mL. Study participants were male (87%), Caucasian (73%), black (15%), and Hispanic (9%). At baseline the median age was 36 years, the median baseline CD4+ cell count was 360 cells/mm3, and median baseline plasma HIV-1 RNA was 4.8 log10 copies/mL. Proportions of patients with plasma HIV-1 RNA less than 400 copies/mL (using Roche AMPLICOR HIV-1 MONITOR Test) through 48 weeks of treatment are summarized in Table 8.<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" width="0.000" ID="id_a2141c77-7163-4154-94db-73f212435b16"><BR>                           <caption ID="id_814cbcb1-5a8e-4ff4-ad87-a4c90c945f82">Table 8. Outcomes of Randomized Treatment Through Week 48 (CNA3005)</caption><BR>                           <col/><BR>                           <col/><BR>                           <col/><BR>                           <tfoot ID="id_8e7d7621-c434-453f-abc5-98f5992bc388"><BR>                              <tr><BR>                                 <td align="left" valign="top" colspan="3" rowspan="1"><BR>                                    <paragraph><BR>                                       <sup>*</sup> Patients achieved and maintained confirmed HIV-1 RNA &lt;400&#160;copies/mL.</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="left" valign="top" colspan="3" rowspan="1"><BR>                                    <paragraph><BR>                                       <sup>&#8224;</sup> Includes viral rebound and failure to achieve confirmed &lt;400&#160;copies/mL by Week 48. </paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="left" valign="top" colspan="3" rowspan="1" styleCode="Lrule Botrule"><BR>                                    <paragraph><BR>                                       <sup>&#8225;</sup> Includes consent withdrawn, lost to follow up, protocol violations, those with missing data, clinical progression, and other.</paragraph><BR>                                 </td><BR>                              </tr><BR>                           </tfoot><BR>                           <tbody><BR>                              <tr ID="id_89fad79e-9bf1-473b-9a64-0be3d110f651"><BR>                                 <td align="center" valign="bottom" rowspan="1" styleCode="Botrule Toprule Rrule"><BR>                                    <paragraph>Outcome</paragraph><BR>                                 </td><BR>                                 <td align="center" valign="bottom" rowspan="1" styleCode="Botrule Rrule"><BR>                                    <paragraph>ZIAGEN plus Lamivudine/Zidovudine</paragraph><BR>                                    <paragraph>(n&#160;=&#160;262)</paragraph><BR>                                 </td><BR>                                 <td align="center" valign="top" rowspan="1" styleCode="Botrule"><BR>                                    <paragraph>Indinavir plus </paragraph><BR>                                    <paragraph>Lamivudine/Zidovudine</paragraph><BR>                                    <paragraph>(n&#160;=&#160;265)</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr ID="id_50473905-0793-4fc9-ba59-db4d5bcdb576"><BR>                                 <td align="left" valign="top" rowspan="1" styleCode="Rrule"><BR>                                    <paragraph>Responder<sup>*</sup><BR>                                    </paragraph><BR>                                 </td><BR>                                 <td align="center" valign="top" rowspan="1" styleCode="Rrule"><BR>                                    <paragraph>49%</paragraph><BR>                                 </td><BR>                                 <td align="center" valign="top" rowspan="1"><BR>                                    <paragraph>50%</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr ID="id_9563bb54-106e-4f4b-a2d4-8695769b587a"><BR>                                 <td align="left" valign="top" rowspan="1" styleCode="Rrule"><BR>                                    <paragraph>Virologic failure<sup>&#8224;</sup><BR>                                    </paragraph><BR>                                 </td><BR>                                 <td align="center" valign="top" rowspan="1" styleCode="Rrule"><BR>                                    <paragraph>31%</paragraph><BR>                                 </td><BR>                                 <td align="center" valign="top" rowspan="1"><BR>                                    <paragraph>28%</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr ID="id_9c5ca42a-f16e-48ca-9a38-9233d8771694"><BR>                                 <td align="left" valign="top" rowspan="1" styleCode="Rrule"><BR>                                    <paragraph>Discontinued due to adverse reactions</paragraph><BR>                                 </td><BR>                                 <td align="center" valign="top" rowspan="1" styleCode="Rrule"><BR>                                    <paragraph>10%</paragraph><BR>                                 </td><BR>                                 <td align="center" valign="top" rowspan="1"><BR>                                    <paragraph>12%</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr ID="id_5189f861-d5cf-4ca5-b57b-e1b0e5e89b60"><BR>                                 <td align="left" valign="top" rowspan="1" styleCode="Botrule Rrule"><BR>                                    <paragraph>Discontinued due to other reasons<sup>&#8225;</sup><BR>                                    </paragraph><BR>                                 </td><BR>                                 <td align="center" valign="top" rowspan="1" styleCode="Botrule Rrule"><BR>                                    <paragraph>11%</paragraph><BR>                                 </td><BR>                                 <td align="center" valign="top" rowspan="1" styleCode="Botrule"><BR>                                    <paragraph>10%</paragraph><BR>                                 </td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>Treatment response by plasma HIV-1 RNA strata is shown in Table 9.<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" width="456.000" ID="id_0ac3ac0a-2676-461b-9e17-68f2035f7cc6"><BR>                           <caption ID="id_23e9f310-ecb7-45e6-84f6-606868cbe6d0">Table&#160;9. Proportions of Responders Through Week 48 By Screening Plasma HIV-1 RNA Levels (CNA3005)</caption><BR>                           <col width="28.9%"/><BR>                           <col width="21.7%"/><BR>                           <col width="13.2%"/><BR>                           <col width="21.7%"/><BR>                           <col width="14.5%"/><BR>                           <tbody><BR>                              <tr ID="id_248178bf-cc71-429e-b283-279a3d7a923b"><BR>                                 <td align="center" valign="bottom" rowspan="2" styleCode="Botrule Toprule Rrule"><BR>                                    <paragraph>Screening </paragraph><BR>                                    <paragraph>HIV-1 RNA</paragraph>(copies/mL)</td><BR>                                 <td align="center" valign="top" colspan="2" rowspan="1" styleCode="Botrule Rrule"><BR>                                    <paragraph>ZIAGEN plus Lamivudine/Zidovudine</paragraph>(n&#160;=&#160;262)</td><BR>                                 <td align="center" valign="top" colspan="2" rowspan="1" styleCode="Botrule"><BR>                                    <paragraph>Indinavir plus </paragraph><BR>                                    <paragraph>Lamivudine/Zidovudine</paragraph>(n&#160;=&#160;265)</td><BR>                              </tr><BR>                              <tr ID="id_8a7d26b8-40a0-4144-9fff-3571c661b2b4"><BR>                                 <td align="center" valign="top" rowspan="1" styleCode="Botrule Rrule">&lt;400&#160;copies/mL</td><BR>                                 <td align="center" valign="top" rowspan="1" styleCode="Botrule Rrule">n</td><BR>                                 <td align="center" valign="top" rowspan="1" styleCode="Botrule Rrule">&lt;400&#160;copies/mL</td><BR>                                 <td align="center" valign="top" rowspan="1" styleCode="Botrule">n</td><BR>                              </tr><BR>                              <tr ID="id_9702801e-edd2-49a2-8736-04e3906fb761"><BR>                                 <td align="justify" valign="top" rowspan="1" styleCode="Rrule">&#8805;10,000 - &#8804;100,000</td><BR>                                 <td align="center" valign="top" rowspan="1" styleCode="Rrule">50%</td><BR>                                 <td align="center" valign="top" rowspan="1" styleCode="Rrule">166</td><BR>                                 <td align="center" valign="top" rowspan="1" styleCode="Rrule">48%</td><BR>                                 <td align="center" valign="top" rowspan="1">165</td><BR>                              </tr><BR>                              <tr ID="id_8bef0be5-ec21-4411-a46e-cbaea6257e61"><BR>                                 <td align="justify" valign="top" rowspan="1" styleCode="Botrule Rrule">&gt;100,000</td><BR>                                 <td align="center" valign="top" rowspan="1" styleCode="Rrule">48%</td><BR>                                 <td align="center" valign="top" rowspan="1" styleCode="Rrule">96</td><BR>                                 <td align="center" valign="top" rowspan="1" styleCode="Rrule">52%</td><BR>                                 <td align="center" valign="top" rowspan="1" styleCode="Botrule">100</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>In subjects with baseline viral load greater than 100,000 copies/mL, percentages of patients with HIV-1 RNA levels less than 50 copies/mL were 31% in the group receiving abacavir vs. 45% in the group receiving indinavir.<BR>                        Through Week 48, an overall mean increase in CD4+ cell count of about 150 cells/mm3 was observed in both treatment arms. Through Week 48, 9 subjects (3.4%) in the group receiving abacavir sulfate (6 CDC classification C events and 3 deaths) and 3 subjects (1.5%) in the group receiving indinavir (2 CDC classification C events and 1 death) experienced clinical disease progression. <BR>                        CNA30021 was an international, multicenter, double-blind, controlled study in which 770 HIV-1-infected, therapy-naive adults were randomized and received either abacavir 600 mg once daily or abacavir 300 mg twice daily, both in combination with lamivudine 300 mg once daily and efavirenz 600 mg once daily. The double-blind treatment duration was at least 48 weeks. Study participants had a mean age of 37 years, were: male (81%), Caucasian (54%), black (27%), and American Hispanic (15%). The median baseline CD4+ cell count was 262 cells/mm3 (range 21 to 918 cells/mm3) and the median baseline plasma HIV-1 RNA was 4.89 log10 copies/mL (range: 2.60 to 6.99 log10 copies/mL).<BR>                        The outcomes of randomized treatment are provided in Table 10.<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" width="0.000" ID="id_ed578646-d5e2-46f1-83cf-055ca70f03cc"><BR>                           <caption ID="id_6362ef75-cd08-45cf-b0ea-5da77f13eab8">Table 10. Outcomes of Randomized Treatment Through Week 48 (CNA30021)</caption><BR>                           <col/><BR>                           <col/><BR>                           <col/><BR>                           <tfoot ID="id_7d796efb-4b2a-4bdf-97e1-95f182493dea"><BR>                              <tr><BR>                                 <td align="left" valign="top" colspan="3" rowspan="1"><BR>                                    <paragraph><BR>                                       <sup>*</sup> Patients achieved and maintained confirmed HIV-1 RNA &lt;50&#160;copies/mL (&lt;400&#160;copies/mL) through Week 48 (Roche AMPLICOR Ultrasensitive HIV-1 MONITOR standard test version 1.0).</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="left" valign="top" colspan="3" rowspan="1"><BR>                                    <paragraph><BR>                                       <sup>&#8224;</sup> Includes viral rebound, failure to achieve confirmed &lt;50&#160;copies/mL (&lt;400&#160;copies/mL) by Week&#160;48, and insufficient viral load response.</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="left" valign="top" colspan="3" rowspan="1" styleCode="Lrule Botrule"><BR>                                    <paragraph><BR>                                       <sup>&#8225;</sup> Includes consent withdrawn, lost to follow up, protocol violations, clinical progression, and other.</paragraph><BR>                                 </td><BR>                              </tr><BR>                           </tfoot><BR>                           <tbody><BR>                              <tr ID="id_bc0294e2-75b1-41a4-8896-f61c7568296c"><BR>                                 <td align="center" valign="bottom" rowspan="1" styleCode="Botrule Toprule Rrule"><BR>                                    <paragraph>Outcome</paragraph><BR>                                 </td><BR>                                 <td align="center" valign="top" rowspan="1" styleCode="Botrule Rrule"><BR>                                    <paragraph>ZIAGEN 600 mg q.d. plus EPIVIR plus Efavirenz</paragraph><BR>                                    <paragraph>(n&#160;=&#160;384)</paragraph><BR>                                 </td><BR>                                 <td align="center" valign="top" rowspan="1" styleCode="Botrule"><BR>                                    <paragraph>ZIAGEN 300 mg b.i.d. plus EPIVIR plus Efavirenz</paragraph><BR>                                    <paragraph>(n&#160;=&#160;386)</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr ID="id_be2ceec2-5e8f-4d9e-96b2-19fc45625cfa"><BR>                                 <td align="left" valign="top" rowspan="1" styleCode="Rrule"><BR>                                    <paragraph>Responder<sup>*</sup><BR>                                    </paragraph><BR>                                 </td><BR>                                 <td align="center" valign="top" rowspan="1" styleCode="Rrule"><BR>                                    <paragraph>64% (71%)</paragraph><BR>                                 </td><BR>                                 <td align="center" valign="top" rowspan="1"><BR>                                    <paragraph>65% (72%)</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr ID="id_2d2413b1-17d7-4c4d-b481-ef85e0283d2b"><BR>                                 <td align="left" valign="top" rowspan="1" styleCode="Rrule"><BR>                                    <paragraph>Virologic failure<sup>&#8224;</sup><BR>                                    </paragraph><BR>                                 </td><BR>                                 <td align="center" valign="top" rowspan="1" styleCode="Rrule"><BR>                                    <paragraph>11% (5%)</paragraph><BR>                                 </td><BR>                                 <td align="center" valign="top" rowspan="1"><BR>                                    <paragraph>11% (5%)</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr ID="id_0f122965-42da-49d1-9aea-676c20e0a0b8"><BR>                                 <td align="left" valign="top" rowspan="1" styleCode="Rrule"><BR>                                    <paragraph>Discontinued due to adverse reactions</paragraph><BR>                                 </td><BR>                                 <td align="center" valign="top" rowspan="1" styleCode="Rrule"><BR>                                    <paragraph>13%</paragraph><BR>                                 </td><BR>                                 <td align="center" valign="top" rowspan="1"><BR>                                    <paragraph>11%</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr ID="id_8a3240d2-7b5a-4851-b077-a92d0ada362a"><BR>                                 <td align="left" valign="top" rowspan="1" styleCode="Botrule Rrule"><BR>                                    <paragraph>Discontinued due to other reasons<sup>&#8225;</sup><BR>                                    </paragraph><BR>                                 </td><BR>                                 <td align="center" valign="top" rowspan="1" styleCode="Botrule Rrule"><BR>                                    <paragraph>11%</paragraph><BR>                                 </td><BR>                                 <td align="center" valign="top" rowspan="1" styleCode="Botrule"><BR>                                    <paragraph>13%</paragraph><BR>                                 </td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>After 48 weeks of therapy, the median CD4+ cell count increases from baseline were 188 cells/mm3 in the group receiving abacavir 600 mg once daily and 200 cells/mm3 in the group receiving abacavir 300 mg twice daily. Through Week 48, 6 subjects (2%) in the group receiving ZIAGEN 600 mg once daily (4 CDC classification C events and 2 deaths) and 10 subjects (3%) in the group receiving ZIAGEN 300 mg twice daily (7 CDC classification C events and 3 deaths) experienced clinical disease progression. None of the deaths were attributed to study medications. <BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     14.2 Pediatric Patients<BR>                     <BR>                        <BR>                           Therapy-Experienced Pediatric Patients: CNA3006 was a randomized, double-blind study comparing ZIAGEN 8 mg/kg twice daily plus lamivudine 4 mg/kg twice daily plus zidovudine 180 mg/m2 twice daily versus lamivudine 4 mg/kg twice daily plus zidovudine 180 mg/m2 twice daily. Two hundred and five therapy-experienced pediatric patients were enrolled: female (56%), Caucasian (17%), black (50%), Hispanic (30%), median age of 5.4 years, baseline CD4+ cell percent greater than 15% (median = 27%), and median baseline plasma HIV-1 RNA of 4.6 log10 copies/mL. Eighty percent and 55% of patients had prior therapy with zidovudine and lamivudine, respectively, most often in combination. The median duration of prior nucleoside analogue therapy was 2 years. At 16 weeks the proportion of patients responding based on plasma HIV-1 RNA less than or equal to 400 copies/mL was significantly higher in patients receiving ZIAGEN plus lamivudine plus zidovudine compared with patients receiving lamivudine plus zidovudine, 13% versus 2%, respectively. Median plasma HIV-1 RNA changes from baseline were -0.53 log10 copies/mL in the group receiving ZIAGEN plus lamivudine plus zidovudine compared with -0.21 log10 copies/mL in the group receiving lamivudine plus zidovudine. Median CD4+ cell count increases from baseline were 69 cells/mm3 in the group receiving ZIAGEN plus lamivudine plus zidovudine and 9 cells/mm3 in the group receiving lamivudine plus zidovudine.<BR>                     <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>